9 7 7 a n a ly s i s Thousands of somatic mutations accrue in most human cancers, and their causes are largely unknown. We recently showed that the DNA cytidine deaminase APOBEC3B accounts for up to half of the mutational load in breast carcinomas expressing this enzyme. Here we address whether APOBEC3B is broadly responsible for mutagenesis in multiple tumor types. We analyzed gene expression data and mutation patterns, distributions and loads for 19 different cancer types, with over 4,800 exomes and 1,000,000 somatic mutations. Notably, APOBEC3B is upregulated, and its preferred target sequence is frequently mutated and clustered in at least six distinct cancers: bladder, cervix, lung (adenocarcinoma and squamous cell carcinoma), head and neck, and breast. Interpreting these findings in the light of previous genetic, cellular and biochemical studies, the most parsimonious conclusion from these global analyses is that APOBEC3B-catalyzed genomic uracil lesions are responsible for a large proportion of both dispersed and clustered mutations in multiple distinct cancers.
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Somatic mutations are essential for normal cells to develop into cancers. Partial and full tumor genome sequences have shown the existence of hundreds to thousands of mutations in most cancers [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . The observed mutation spectrum is the result of DNA lesions that either escaped repair or were misrepaired. This spectrum can be used to help determine the cause or source of the initial damage. For instance, the cytosine-to-thymine transition bias in skin cancers can be explained by a mechanism in which ultraviolet (UV)-induced lesions-cyclobutane pyrimidine dimers (C*C, C*T, T*C or T*T, where asterisks denote UV-induced lesions between adjacent pyrimidines)-are bypassed by DNA polymerase-catalyzed insertion of two adenine bases opposite each unrepaired lesion 11 . A second round of DNA replication or excision and repair of the pyrimidine dimer results in cytosine-to-thymine transitions. Notably, the nature of this type of DNA damage dictates that each resulting cytosine-to-thymine transition occurs in a dipyrimidine context, with each mutated cytosine invariably flanked on the 5′ or the 3′ side by a cytosine or thymine. A similar rationale combining observed mutation spectra and knowledge of biochemical mechanisms may be used to delineate other sources of DNA damage and mutation in human cancers.
Nonrandom mutation patterns, such as CG base pairs being more frequently mutated than AT base pairs [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] and the occurrence of strand-coordinated clusters of cytosine mutations 9, 12, 13 (strandcoordinated mutations are those that occur together on a single strand of the DNA double helix), are also observed in other types of cancer. Spontaneous hydrolytic deamination of cytosine to uracil may explain a subset of these events but not the majority, as most occur outside of CpG dinucleotide motifs that can be methylated (the sites most prone to spontaneous deamination), and the occurrence of these mutations in clusters is highly nonrandom. Another possible source of these mutations is enzyme-catalyzed cytosine-to-uracil deamination by one or more of the nine active DNA cytidine deaminases encoded by the human genome. Such a mechanism was originally hypothesized when the DNA deaminase activity of these enzymes was discovered 14 and was recently highlighted with demonstrations of clustered mutations in breast, head and neck, and other cancers 9, 12, 13 . These mutational clusters have been named kataegis, as their sporadic but concentrated nature bears a likeness to rain showers 9 . Although enzymatic deamination has been implicated in this phenomenon, the actual enzyme responsible has not been determined.
Enzyme-catalyzed DNA cytosine-to-uracil deamination is central to both adaptive and innate immune responses. B lymphocytes use activation-induced deaminase (AID) to create antibody diversity by inflicting uracil lesions in the variable regions of expressed immunoglobulin genes, which are ultimately processed into all six types of base-substitution mutations 15, 16 (somatic hypermutation). AID also creates uracil lesions in antibody gene switch regions that lead to DNA breaks and the juxtaposition of the expressed and often mutated variable region next to a new constant region (isotype switch recombination) 15, 16 . In humans, seven related enzymes-APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G and APOBEC3H-combine to provide innate immunity to a variety of DNA-based parasitic elements 17, 18 . A well-studied example is the cDNA replication intermediate of HIV-1, which during reverse transcription is vulnerable to enzymatic deamination by at least three different APOBEC3 proteins 19, 20 . APOBEC1 also has a similar capacity for viral cDNA deamination, and it is the only family member known to have a biological role in cellular mRNA editing [21] [22] [23] [24] . The more distantly related proteins APOBEC2 and APOBEC4 have yet to elicit enzymatic activity. In total, 9 of the 11 APOBEC family members have demonstrated DNA deaminase activity in a variety of biochemical and biological assay systems 14,25-29 . Evidence for APOBEC3B mutagenesis in multiple human cancers a n a ly s i s However, a possible drawback of encoding nine active DNA deaminases could be chromosomal DNA damage and, ultimately, mutations that lead to cancer 14 . AID has been linked to B cell tumorigenesis through off-target chromosomal deamination as well as the triggering of translocations between the expressed heavy chain locus and various oncogenes 30 . Transgenic expression of AID causes tumor formation in mice 31 , as does transgenic expression of APOBEC1 (ref. 32) . Most recently, we showed that APOBEC3B is upregulated in breast tumors and is correlated with a doubling of both cytosine-to-thymine and overall base-substitution mutation loads 33 . Because AID and APOBEC1 are expressed in a tissue-specific manner and there is no reason to suspect developmental confinement of APOBEC3B, we hypothesized that APOBEC3B may be a general mutagenic factor affecting the genesis and evolution of many different cancers. This hypothesis is supported by studies indicating that APOBEC3B is expressed in many different cancer cell lines [33] [34] [35] , in contrast to its relatively low expression in 21 normal human tissues spanning all major organs 33, 35, 36 . This DNA mutator hypothesis is additionally supported by the fact that APOBEC3B is the only deaminase family member with constitutive nuclear localization 33, 37 .
Here we test this mutator hypothesis by performing a global analysis of all available DNA deaminase family member expression data and exomic mutation data from 19 different cancers representing over 4,800 tumors and 1,000,000 somatic mutations. Mutation frequencies, local sequence contexts and distributions, including kataegis events, were analyzed systematically for each tumor and cancer type. In addition, we calculated the hierarchical distances between the deamination signature of recombinant APOBEC3B derived from biochemical experiments 33 and the observed frequencies of cytosine mutation spectra in all 19 cancer types. Taken together, these analyses converge upon APOBEC3B as the most likely cause of a large fraction of both dispersed and clustered cytosine mutations in six distinct cancers.
RESULTS
As a first test of the hypothesis that APOBEC3B is a general endogenous cancer mutagen, we performed a comprehensive analysis of the expression profiles of all 11 APOBEC family members across a panel of 19 distinct tumor types, including breast cancer as a positive control 33 (Table 1 and Supplementary Fig. 1 ). The expression values for each target mRNA were normalized to those of the constitutive housekeeping gene TBP (encoding TATA-binding protein) to enable quantitative comparisons between RNA sequencing (RNA-seq) and quantitative RT-PCR (qRT-PCR) data sets and to provide controls in the few instances where RNA-seq values for normal tissues were not available publicly (Online Methods).
Several cancers showed APOBEC3B expression levels comparable to those in corresponding normal tissues (Fig. 1, Table 1 , Supplementary Fig. 1 and Supplementary Table 1 ). Prostate and renal clear-cell carcinomas showed statistically significant upregulation of APOBEC3B in the tumors, albeit with median expression values that were only a fraction of the TBP levels. In contrast, six different cancers showed evidence of strong APOBEC3B upregulation in the majority of tumors of the breast, uterus, bladder, head and neck, and lung (adenocarcinoma and squamous cell carcinoma) (P < 0.0001 by Mann-Whitney U test). Other cancers, such as cervical and skin, also showed high APOBEC3B levels, but a lack of data for corresponding normal tissues precluded statistical analysis. A total of ten cancers showed a median level of APOBEC3B upregulation greater than that of the intended positive control, breast cancer. npg a n a ly s i s
This finding was particularly notable for bladder, head and neck, both lung carcinomas and cervical cancers. The second major prediction of the APOBEC mutator hypothesis is the occurrence of chromosomal DNA cytosine-to-uracil deamination, which should result in strong biases toward mutations at CG base pairs. Such mutational events may be either transitions or transversions because genomic uracil bases can either directly template the insertion of adenine bases during DNA replication, or, if converted to abasic sites by uracil DNA glycosylase, the lesions become noninstructional, and error-prone polymerases may insert an adenine, thymine or cytosine opposite the abasic site (most often adenine, following the A rule). In both scenarios, an additional round of DNA synthesis or repair can yield either transitions or transversions at CG base pairs (including CG-to-TA, CG-to-GC and CG-to-AT base-pair mutations).
Notably, the fraction of mutations at CG base pairs ranges considerably, from a low of 60% in renal cancers to a high of approximately 90% in skin, bladder and cervical cancers (Fig. 2a) . The massive bias in skin cancers is largely attributable to error-prone DNA synthesis (adenine insertion) opposite cyclobutane pyrimidine dimers caused by UV light 11 . However, the biases observed in urogenital carcinomas, such as bladder and cervical cancers, are probably not due to UV light but more likely to an alternative mutagenic source such as enzymatic DNA deamination. Indeed, the top five tumor types with CG base pair-dominated mutation spectra were among the top six tumors in terms of APOBEC3B expression (compare Figs. 1 and 2a) . A possible mechanistic relationship is further supported by a positive correlation between the overall proportion of mutations occurring at CG base pairs and median APOBEC3B levels (P = 0.0031, r = 0.64 by Spearman's correlation; Fig. 2b ). The positive correlation is notable given the fact that all available data were included in the analysis and multiple variables could have undermined a positive correlation, such as known mutational sources (UV light in skin cancer), undefined mutational sources (in glioma with the sixth highest CG base-pair mutation bias and lowest APOBEC3B levels) and differential DNA repair capabilities among the distinct tumor types.
DNA deaminases such as APOBEC3B are strongly influenced by the bases adjacent to the target cytosine, particularly at the immediate 5′ position. For instance, AID prefers 5′ adenine or guanine bases, APOBEC3G prefers 5′ cytosine bases and other family members prefer 5′ thymine bases [38] [39] [40] . We recently showed that recombinant APOBEC3B prefers 5′ thymine bases and strongly disfavors 5′ purines, whereas, on the 3′ side, it prefers adenine or guanine bases and disfavors pyrimidines 33 (Fig. 3a) . Therefore, the third prediction of the APOBEC mutator hypothesis is that cancers affected by enzymatic deamination should show nonrandom nucleotide distributions immediately 5′ and 3′ of mutated cytosine bases and that these signatures can then be used with expression information, additional mutation data and existing literature and biochemical constraints to identify the enzyme responsible.
We therefore performed a global analysis of sequence signatures for all available cytosine mutation data from the top 50% of APOBEC3B-expressing tumors for each tumor type (this expression cutoff was chosen to minimize the impact of unrelated mutational mechanisms). These mutation data were first compiled and subjected to hierarchical cluster analysis to group tumors with similar cytosine mutation signatures (Fig. 3a) . Short Euclidean distances (smaller measures) between the mutation signatures of different tumors indicated a high degree of concordance, thereby implying similar mutational patterns (Supplementary Table 2 lists the calculated values). Bladder and cervical cancers, two of the top APOBEC3B-expressing cancers, had cytosine mutation signatures notably similar to each other and to that of recombinant APOBEC3B protein. This relationship is illustrated by strong mutation biases at TCA motifs (with the targeted base underlined), which match the enzyme's optimal in vitro substrate. The two lung carcinomas, breast, and head and neck cancers also had cytosine mutation signatures that strongly resembled the preference of recombinant APOBEC3B protein ( Fig. 3a and Supplementary Table 2) . Several cancers had cytosine mutation signatures with an intermediate relatedness npg a n a ly s i s to the motif for recombinant APOBEC3B (renal papillary, thyroid, ovarian, renal clear-cell, glioblastoma multiforme (GBM) and skin cancers). In further contrast, the seven remaining cancers, ranging from uterine to colon, had cytosine mutations with the largest separation from the motif for recombinant APOBEC3B ( Fig. 3a and Supplementary Table 2 ). 33 . Skin cancer and the bottom seven cancers (highlighted by dashed boxes) have obviously different cytosine mutation spectra. a n a ly s i s
We next separated each composite mutation distribution into the 16 individual local trinucleotide contexts to further resolve cytosinefocused mutational mechanisms that might influence each cancer. Bladder, cervical, lung squamous cell carcinoma, lung adenocarcinoma, head and neck, and breast cancers all shared strong bias for TCN mutation signatures (where N is any base), with the strongest bias for TCA of the four possibilities (Fig. 3b) . A background of other mutations was apparent in the two types of lung cancer, possibly associated with tobacco carcinogens or other mutational mechanisms. The next most obvious signature occurred in skin cancer, as expected, with cytosine-to-thymine transitions predominating in dipyrimidine contexts (Fig. 3b) . Only two other obvious cytosine-focused mutation patterns were evident. Cytosine-to-thymine mutations in CG contexts dominated at least seven types of cancer, consistent with a CG-targeted mechanism such as spontaneous deamination of methylcytosine (Fig. 3b) . Finally, uterine, low-grade glioma, rectal and colon cancers had an inordinate number of cytosine-to-adenine transversions in YCT contexts, where Y is either C or T, consistent with at least one additional distinct cytosine-focused mutational mechanism (for example, POLE proofreading domain variants have been implicated in a subset of colorectal tumors 41 ) .
A fourth prediction of a general mutator hypothesis is that tumor mutation loads correlate with APOBEC3B expression levels. To test this possibility on a global level, we used median mutation loads for each tumor type and median APOBEC3B expression values. Median values were chosen to ensure the inclusion of all data, yet simultaneously minimized the impact of uncontrollable variables, such as other mutational mechanisms, jackpot effects, bottlenecks and durations of tumor existence. As recently reviewed in ref. 42 , mutation loads varied considerably within each tumor type and between the different cancers, with more than a full log difference from the bottom to the top of this range (acute myeloid leukemia to skin cancer; Fig. 4a) . However, despite this wide variation, a strong positive correlation was found between median mutation loads and APOBEC3B expression levels (P = 0.0013, r = 0.68 by Spearman's correlation; Fig. 4b ). This result is consistent with the possibility that APOBEC3B may be a general endogenous mutagen that contributes to multiple human cancers, albeit, as outlined above, it clearly contributes much more to a particular subset of cancers. A dominant role for APOBEC3B in a subset of cancers is further supported by significant correlations between mutation loads and APOBEC3B expression levels when these analyses were performed for each cancer type on a tumor-by-tumor basis (Supplementary Figs. 2 and 3) .
A final prediction of a general APOBEC mutator hypothesis is that affected cancers should bear evidence of strand-coordinated clusters of cytosine mutations 9,12,13 . As proposed in ref. 12 , clusters can be defined as two or more mutation events within a 10-kb window. By this criterion, every cancer showed evidence of cytosine mutation clustering, with a large range between different cancer types (0.016 to 38 cytosine mutation clusters per tumor). However, it is necessary to apply an additional calculation to take into consideration the sequence length of each cluster, which also varies substantially and can result in the inclusion of false positives (see ref. 12 and Online Methods). This additional filter yielded a much smaller number of likely kataegis events, ranging from 0.002 clusters per ovarian carcinoma to 4.4 clusters per uterine tumor (Table 1) . Notably, the number of mutations grouped into kataegis events was a relatively small percentage of the total number of cytosine mutations for each cancer (at most 7.9%). However, the mere existence of clustered cytosine mutations in nearly every cancer provides further evidence npg a n a ly s i s for APOBEC involvement. For most cancers, this is likely to be APOBEC3B, as the average number of kataegis events per tumor correlated positively with median APOBEC3B expression levels (P = 0.017, r = 0.54 by Spearman's correlation; Fig. 4c ). The six cancer types with cytosine mutation signatures that grouped most closely with that of recombinant APOBEC3B-bladder, cervix, lung (adenocarcinoma and squamous cell carcinoma), head and neck, and breast-all showed strong evidence of kataegis, with means of 3.0, 2.5, 0.79, 0.81, 0.66 and 0.16 clusters per tumor, respectively. It is notable that breast cancer is at the low end of this range, but 50-fold higher frequencies would be expected if full genomic sequences had been available (concordant with the analyses in ref. 9 ). Notably, low-grade gliomas and uterine carcinomas were clear outliers in this analysis, consistent with the close hierarchical clustering of their cytosine mutation signatures (distant from that of recombinant APOBEC3B) and strongly suggesting a distinct mutational mechanism in these cancers.
DISCUSSION
We performed an unbiased analysis of all available DNA deaminase expression profiles and cytosine mutation patterns in 19 different cancer types to try to explain the origin of the cytosine-biased mutation spectra and clustering observed in many different cancers [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 13 . Observed cytosine mutation patterns were compared using a hierarchical clustering method to group cancers with similar mutation patterns. Six distinct cancer types-bladder, cervical, lung squamous cell carcinoma, lung adenocarcinoma, head and neck, and breastclearly stood out, with elevated APOBEC3B expression in the majority of tumors, strong overall CG base-pair mutation biases, cytosine mutation contexts that closely resemble the deamination signature of recombinant APOBEC3B and evidence of kataegis events. The most parsimonious explanation for this convergence of independent data sets is that APOBEC3B-dependent genomic DNA deamination is the direct cause of most of the cytosine mutations in these types of cancer. These data are consistent with a general mutator hypothesis in which APOBEC3B mutagenesis has the capacity to broadly shape the mutational landscapes of at least six distinct tumor types and possibly also those of several others, albeit to lesser extents. The large data sets analyzed here support a model in which upregulated levels of APOBEC3B cause genomic cytosine-to-uracil lesions, which may be processed into a variety of mutagenic outcomes 33 ( Supplementary Fig. 4) . In most cases, uracil lesions are repaired faithfully by canonical base-excision repair. However, in some instances, uracil lesions may template the insertion of adenine bases during DNA synthesis, which might result in cytosine-to-thymine transitions (guanine-to-adenine transitions on the opposing strand). In other cases, genomic uracil bases may be converted to abasic sites by uracil DNA glycosylase. These lesions are non-instructional, such that DNA polymerases, in particular, translesion DNA polymerases, may place any base opposite, with an adenine leading to a transition and a cytosine or thymine leading to a transversion. In addition, uracil lesions that are processed into nicks through the concerted action of a uracil DNA glycosylase and an abasic site endonuclease can result in single-or double-stranded DNA breaks, which are substrates for recombination repair and are undoubtedly intermediates in the formation of cytosine mutation clusters (kataegis) 9,12,13 and larger-scale chromosomal aberrations such as translocations.
The significant positive correlations between APOBEC3B expression levels and the percentage of mutations at CG base pairs, the overall mutation loads and the number of kataegis events combine to suggest that most cancers are affected by APOBEC3B-dependent mutagenesis, but unambiguous determinations were not possible for several cancers for a variety of reasons. Skin cancer, for example, has the fifth highest APOBEC3B expression level and clear evidence of kataegis, but it also has a strong dipyrimidine-focused cytosineto-thymine mutation pattern that could easily eclipse an APOBEC3B deamination signature. APOBEC3B may help explain melanomas that occur with minimal UV exposure 43 . Several other cancers, including uterine, rectal, stomach and ovarian, also have significant APOBEC3B upregulation and evidence of kataegis, which combine to suggest direct involvement of APOBEC3B, but the trinucleotide cytosine mutation motifs were too distantly related to that of the recombinant enzyme to enable unambiguous associations. Therefore, additional large data sets such as high-depth full-genome sequences will be required to distinguish an APOBEC3B-dependent mechanism unambiguously from the multiple other mechanisms contributing to these tumor types.
We note that we have not completely excluded the possibility of other DNA deaminase family members contributing to mutation in cancer, but, apart from AID in B cell cancers 30 , roles for other APOBECs are unlikely to be as great as those of APOBEC3B, namely because other APOBECs (i) have no reported enzymatic activity (APOBEC2 and APOBEC4), (ii) have tissue-restricted expression profiles (AID, APOBEC3A, APOBEC1, APOBEC2 and APOBEC4) 33, 35, 36, [44] [45] [46] [47] [48] , (iii) are localized to the cytoplasmic compartment (APOBEC3A, APOBEC3D, APOBEC3F, APOBEC3G and APOBEC3H) 29, 37, 49, 50 and (iv) have a completely different intrinsic preference for bases surrounding the target cytosine than APOBEC3B (AID and APOBEC3G prefer 5′ RC and 5′ CC, respectively, where R is either A or G) 33, [38] [39] [40] . Thus, taken together with the comprehensive analyses presented here of expression data (Fig. 1) , CG base-pair mutation frequencies (Fig. 2) , local cytosine mutation signatures (Fig. 3) , overall mutation loads (Fig. 4) and kataegis ( Fig. 4c and Table 1 ), all available data converge on the conclusion that APOBEC3B is a major source of mutation in multiple human cancers. This knowledge provides a foundation for future studies focused on each cancer type and subtype to further delineate the impact of this potent DNA mutator on each cancer genome and on associated therapeutic responses and patient outcomes. a n a ly s i s Reprints and permissions information is available online at http://www.nature.com/ reprints/index.html.
